Twist Bioscience Just Sold $300 Million of a Story That Isn't Supposed to Need Money Yet

Here's the odd thing. Twist Bioscience spent yesterday telling investors it was about to turn a corner. Record revenue, raised guidance, adjusted EBITDA breakeven coming in the final quarter. The stock jumped 10.4%. Everyone was celebrating the transition from growth-company red ink to profitable-growth-company green.

Then, the day after close, Twist announced a public offering of up to $250.0 million of shares.

If the story is that profitability is around the bend, you don't normally raise a nine-figure chunk of equity the next morning.

-

The basic point is that Twist has $167 million in cash, cash equivalents, and short-term investments. It lost $35 million in the quarter on a GAAP basis. Its adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough proxy for cash operating profit - was still negative $11.3 million. And yet the stock has rallied from $23 a year ago to roughly $100 today, and management decided this is the right moment to convert that enthusiasm into hard capital.

This is not a sign of weakness. It's the rational thing to do. When your stock has gone up 213 percent year-to-date and your narrative around AI-enabled drug discovery is at peak attention, you sell equity. You don't wait for the day the market stops caring about synthetic biology and starts asking again when you'll actually be profitable.

Let's walk through the plumbing. The offering starts at $250.0 million with a 30-day option for another $37.5 million, which gets you to roughly $287.5 million. Goldman Sachs is leading, with William Blair, Leerink Partners, and Guggenheim as co-bookrunners. Twist has about 61.1 Mil diluted shares. At a price near $100 per share, the offering would add roughly 3 million shares, or around 5 percent dilution to existing holders. The new cash would more than triple Twist's balance sheet firepower, pushing it from $167 million to roughly $460 million or so after fees.

The stated use of proceeds is research and development, manufacturing capacity expansion, new product offerings, and general corporate purposes. That's the standard shelf-registration language. The real use of proceeds is runway and optionality: enough cash that Twist doesn't have to sell equity again for a long time, even if the AI drug-discovery story bumps along or the broader biotech market cools.

-

The funny part - and here's where you want to pay attention - is the insider trading. In the past six months, Twist insiders have executed 76 transactions on the open market. Zero of them have been purchases. All 76 have been sales.

The CEO, Emily Leproust, sold $8.5 million worth of shares. The president and COO sold $4.9 million. The SVP of human resources sold $4.6 million. Every named executive with available data has been trimming.

This isn't inherently suspicious - option exercises and tax withholding can generate selling pressure without signaling pessimism - but the sheer one-way nature of it is worth noting. Management is telling the market "we're about to be profitable" while systematically reducing their own equity exposure. The company is also raising a massive round of new equity from the market. These two things together don't mean anything sinister, but they do make the "we're turning the corner" pitch feel more like a capital-markets move than a fundamental inflection point.

Investor: We thought we were buying a company that's about to be cash-flow positive. Management: Sure, but you're also buying into a balance sheet that's worth fortifying today while the stock is at $100.

That's not a lie. It's just a different sentence than the one that appears in the press release.

-

So what's the machine actually doing?

Twist makes synthetic DNA. It prints custom genetic sequences on silicon chips and ships them to pharma companies, academic labs, and diagnostics firms. The business is growing fast - 23 percent year-over-year revenue, 14 consecutive quarters of growth, 52.8 percent gross margins that are improving sequentially. The hot new angle is AI-enabled drug discovery, where pharma companies are using generative AI to design novel molecules and then sending those designs to Twist for physical synthesis. Management says this segment saw triple-digit order growth in fiscal 2026 and expects the same pattern in fiscal 2027.

None of that is bad news. The business is real and growing.

But here's the thing that makes the offering worth sitting with: Twist has been dilutive before. Those dilutive events have occurred when the stock was elevated relative to fundamentals and the AI drug discovery story didn't even exist yet. The pattern is: tell a compelling growth story, wait for the stock to run, raise equity at a premium valuation, deploy the cash into R&D and capacity, repeat. It's not a scam; it's the standard biotech-capital-recycling model. You raise cheap capital when the market loves your narrative and deploy it before you strictly need it. The difference between a good company and a bad company running this machine is whether the R&D and manufacturing investment actually compounds into durable revenue and margins.

-

The question for existing shareholders is whether 5 percent dilution today is worth $300 million of runway and the optionality it buys. If the AI drug discovery story delivers on management's triple-digit growth projections and margins hold above 52 percent, the answer is yes - the dilution washes out as the earnings base expands. If the growth normalizes or the EBITDA breakeven slips beyond Q4, the answer gets murkier, because $300 million of raised equity at today's valuation is a lot of money to justify with a company that still hasn't shown a cash-profit quarter.

The options market doesn't seem panicked. Implied volatility is sitting around 44.5 percent, and the put-to-call volume ratio is a low 0.36, suggesting traders aren't rushing to hedge downside. The stock opened at its 52-week high of $106.58 before settling back to around $99, a modest pullback for a company just raising $300 million.

The structural judgment is this: Twist isn't raising money because it's in trouble. It's raising money because the market is temporarily pricing it like it isn't - and management wants to lock that premium in while it can. That's a disciplined capital allocation move, not a distressed one. But it's also a signal that management thinks $100 is a better price than whatever the stock is worth in a year, after the AI enthusiasm cools a notch and profitability turns out to be a longer project than yesterday's press release suggested.

The company that prints DNA is also, today, printing stock. The question is whether the DNA business grows fast enough to make that print job look prescient rather than expensive.